D C Tormey|T P Waalkes - JoVE Visualize

Showing results (101-110 of 170) with videos related to

Pageof 17

Sort By:

Cancer|October 1, 1989

Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group StudyR T Skeel, J W Andersen, D C Tormey, et al.

Cancer|December 1, 1982

Biological markers and small cell carcinoma of the lung: a clinical evaluation of urinary ribonucleosidesT P Waalkes, M D Abeloff, D S Ettinger, et al.

Journal of the National Cancer Institute|August 1, 1976

Beta-aminoaciduria in patients with Burkitt's lymphomaT P Waalkes, C W Gehrke, D B Lakings, et al.

European Journal of Cancer & Clinical Oncology|December 1, 1982

Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lungT P Waalkes, M D Abeloff, D S Ettinger, et al.

Annals of Internal Medicine|September 1, 1985

Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placeboF J Cummings, R Gray, T E Davis, et al.

Cancer|April 1, 1976

Mediastinoscopy: a diagnostic aid in metastatic carcinoma of the breastJ P Neifeld, J N Ingle, D C Tormey, et al.

American Journal of Clinical Oncology|December 1, 1995

Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group studyM A Gertz, L A Kalish, R A Kyle, et al.

Cancer Clinical Trials|January 1, 1981

Vindesine. A phase II trial in advanced breast cancer patientsH I Robins, D C Tormey, M J Skelley, et al.

Breast Cancer Research and Treatment|December 1, 1988

Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsR R Love, R B Mazess, D C Tormey, et al.

Cancer|June 15, 1986

Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoidsA Y Chang, J P Kuebler, K J Pandya, et al.

Pageof 17

Showing results (101-110 of 170) with videos related to

Sort By:

Pageof 17

Cancer|October 1, 1989

Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group StudyR T Skeel, J W Andersen, D C Tormey, et al.

Cancer|December 1, 1982

Biological markers and small cell carcinoma of the lung: a clinical evaluation of urinary ribonucleosidesT P Waalkes, M D Abeloff, D S Ettinger, et al.

Journal of the National Cancer Institute|August 1, 1976

Beta-aminoaciduria in patients with Burkitt's lymphomaT P Waalkes, C W Gehrke, D B Lakings, et al.

European Journal of Cancer & Clinical Oncology|December 1, 1982

Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lungT P Waalkes, M D Abeloff, D S Ettinger, et al.

Annals of Internal Medicine|September 1, 1985

Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placeboF J Cummings, R Gray, T E Davis, et al.

Cancer|April 1, 1976

Mediastinoscopy: a diagnostic aid in metastatic carcinoma of the breastJ P Neifeld, J N Ingle, D C Tormey, et al.

American Journal of Clinical Oncology|December 1, 1995

Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group studyM A Gertz, L A Kalish, R A Kyle, et al.

Cancer Clinical Trials|January 1, 1981

Vindesine. A phase II trial in advanced breast cancer patientsH I Robins, D C Tormey, M J Skelley, et al.

Breast Cancer Research and Treatment|December 1, 1988

Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two yearsR R Love, R B Mazess, D C Tormey, et al.

Cancer|June 15, 1986

Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoidsA Y Chang, J P Kuebler, K J Pandya, et al.

Pageof 17